Alto Neuroscience develops clinical-stage precision medicines for neuropsychiatric disorders, using its Precision Psychiatry Platform™ to analyze EEG activity, neurocognitive assessments, wearable data and other biomarkers that may identify patient populations for its product candidates.
Company news centers on clinical data, trial initiations and pipeline decisions for programs including ALTO-207 in treatment-resistant depression and major depressive disorder, ALTO-101 in cognitive impairment associated with schizophrenia, and other candidates for bipolar depression, schizophrenia and mental health conditions. Updates also cover financial results, capital activity, regulatory designations, medical-meeting presentations and investor-conference participation.
Alto Neuroscience (NYSE: ANRO) reported a third-quarter net loss of $25.124 million as it advanced its depression treatment pipeline. The loss compared with $14.181 million a year earlier; loss per share widened to $0.54 from $0.52. Cash, cash equivalents and restricted cash reached $319.844 million at September 30, 2026. Alto expects cash to fund planned operations through 2030.
A July offering raised $100.0 million gross to help expand ALTO-207 development. Alto expects PACE-1 Phase 2b results in 2H 2027, with Phase 3 adjunctive and monotherapy trials starting in early 2027 and 2H 2027, respectively, pending FDA alignment. Phase 1 and blinded PACE-1 safety results are expected in late 2026 or early 2027 following FDA feedback. ALTO-300 and ALTO-100 Phase 2b results are expected in 1H 2027 and mid-2027, respectively.
Alto Neuroscience (ANRO) granted a new employee an option to purchase 50,000 common shares on November 3, 2026.
The award under the 2025 Inducement Plan was an inducement to join Alto under NYSE Rule 303A.08. The option has a $22.70 exercise price and a 10-year term. It vests over four years: 25% on the first anniversary of the vesting commencement date, followed by equal monthly installments over the next 36 months. Each installment requires the employee’s continued service.
Alto Neuroscience (ANRO) announced that management will participate in two upcoming healthcare investor conferences through fireside chats and one-on-one meetings.
The Stifel presentation is scheduled for November 11, 2026, at 8:00 AM ET in New York. The Jefferies London presentation is scheduled for November 19, 2026, at 9:30 AM GMT in London. Live webcasts will be available through Alto’s investor website, with replays following the presentations.
Alto Neuroscience (ANRO) will participate in three investor-focused healthcare events in September 2026, featuring management presentations and discussions.
The company will join the H.C. Wainwright 28th Annual Global Healthcare Conference with a fireside chat and one-on-one meetings on September 14, 2026 at 9:30 a.m. ET, held in New York and virtually. Alto will present at Baird’s 2026 Global Healthcare Conference on September 15, 2026 at 9:40 a.m. ET in New York, followed by a fireside chat at TD Cowen’s 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026 at 3:00 p.m. ET, held virtually. Presentations will be available via live webcast and replay in the Investors section of Alto’s website.
Alto Neuroscience (NYSE: ANRO) has promoted Nick Smith to the combined role of president and chief financial officer, effective August 26, 2026. He will continue to lead finance and oversee corporate strategy and business development, reporting to founder and CEO Amit Etkin.
Smith joined Alto in 2021 as chief business officer and became CFO in 2022. According to Alto Neuroscience, he has led corporate development and capital strategy, including the company’s initial public offering, the May 2025 acquisition of ALTO-207, and subsequent financings supporting that program and the broader pipeline.
Alto Neuroscience (NYSE: ANRO) reported second quarter 2026 results, highlighted by expansion of ALTO-207 development and strengthened liquidity. An additional Phase 3 trial of ALTO-207 as monotherapy in treatment-resistant depression is planned for 2H 2027, alongside an ongoing potentially registrational Phase 2b adjunctive trial with topline data expected in 2H 2027.
Independent PRIME-PRAXOL data published in Nature Medicine showed significant pramipexole effects on anhedonia and depression, supporting the dopaminergic mechanism underlying ALTO-207. Alto completed an approximately $100 million equity financing in July 2026, resulting in pro forma cash of about $338 million, which is expected to fund planned operations through 2030. Phase 2b trials for ALTO-300 in major depressive disorder and ALTO-100 in bipolar depression remain on track for 2027 readouts. For Q2 2026, Alto reported R&D expenses of $22.1 million, G&A of $7.0 million, and a net loss of $27.6 million, with cash, cash equivalents, and restricted cash of $244.2 million as of June 30, 2026.
Alto Neuroscience (NYSE: ANRO) priced an underwritten registered direct offering of 3,776,436 common shares at $26.48 per share, for expected gross proceeds of about $100.0 million before fees. All shares are offered by Alto, and closing is targeted for July 14, 2026, subject to customary conditions.
According to Alto, net proceeds, together with existing cash, will be used to accelerate and expand clinical development of ALTO-207, including a planned additional Phase 3 monotherapy trial in treatment-resistant depression, and for general working capital. The financing is led by EcoR1 Capital with participation from new and existing healthcare investors.
Alto Neuroscience (NYSE: ANRO) highlighted a Nature Medicine publication of PRIME-PRAXOL, an independent, randomized, placebo-controlled trial of pramipexole in mood disorders with anhedonia.
Pramipexole significantly reduced anhedonia on SHAPS (Hedges’ g=0.62, p=0.006), with benefits on DARS and AES-S sustained over six months and larger effects in the MDD subgroup. High nausea rates (~60%) underscore the rationale for ALTO-207, which combines pramipexole with ondansetron; a potentially pivotal Phase 2b trial in treatment-resistant depression is ongoing with data expected in 2H 2027.
Alto Neuroscience (NYSE: ANRO) appointed Andrew Miller, Ph.D., founder of Karuna Therapeutics, to its Board of Directors effective May 27, 2026. Alto is a clinical-stage company developing precision medicines for neuropsychiatric disorders, including a potentially pivotal Phase 2b trial of ALTO-207 in treatment-resistant depression.
Dr. Miller led R&D at Karuna through its $14 billion acquisition by Bristol Myers Squibb, was lead inventor of KarXT/COBENFY for schizophrenia, and brings extensive neuropsychiatric drug development and corporate strategy experience to support Alto’s pipeline.
Alto Neuroscience (NYSE: ANRO) announced that founder and CEO Amit Etkin, M.D., Ph.D. received the Transformational Research Award from the Columbia University VP&S Alumni Association. The honor recognizes alumni making major biomedical research contributions within 25 years of graduation.
Etkin leads Alto’s Precision Psychiatry Platform and a clinical-stage pipeline in multiple mood and psychiatric disorders, with several mid- to late-stage data readouts anticipated over the next two years.